Company profile
US WorldMeds, LLC
Privately held: no public share price
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
afamitresgene autoleucel(TECELRA) | Approved | —Cell therapy | Soft Tissue Sarcoma Synovial Sarcoma |
| Phase 2 | —Cell therapy | Soft Tissue Sarcoma Myxoid/Round Cell Liposarcoma |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.